GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its PARP inhibitor Zejula (niraparib). Previously, several other firms were rumoured ...

Now, GSK is ready to play catch-up after nabbing its own FDA approval. The FDA approved the British drugmaker's Penmenvy vaccine to protect people ages 10 to 25 against meningococcal serogroups A ...

Feb 15 (Reuters) - The U.S. Food and Drug Administration approved British drugmaker GSK's (GSK.L), opens new tab combination vaccine to protect against meningococcal infection for use in people ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

Ovarian cancer continues to pose a significant challenge in the medical field, remaining one of the leading causes of death ...

Teva Pharmaceutical Industries Ltd. ADR-2.29% $19.01B ...